🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

"My patients, and their families, deserve to know that they will get the care they need without delay" -Jason Westin, MD FACP FASCO in testimony to the Senate Finance Committee on the ongoing #drugshortages crisis. Tell Congress to take action NOW: brnw.ch/21wF2C6 #ASCOAdvocacy

N-AVD vs BV-AVD in older patients with #Hodgkin #lymphoma. No words needed. To me, the new SoC #lymsm #ASH23

Today on #InternationalWomensDay, we're recognizing the leadership and expertise of the women who serve on LRF's Scientific Advisory Board, world-renowned lymphoma experts who chart the course for our research programming. For more about our SAB, visit: lymphoma.org/aboutlrf/sab/

Starting Now: Targeting CD19 and ROR1 in B-Cell Lymphoma Moderated by Dr. Jeff Sharman Jeff Sharman

Brian Hill provides an excellent overview of a new genomic approach to DLBCL categorization and an ambitious plan for LymphoMatch. Broad participation among US cooperative groups will be key to enroll the 2500 patients needed to reach the target statistical power.

FDA Approves Cilta-Cel for R/R Multiple Myeloma After at Least One Prior Line of Therapy onclive.com/view/fda-appro… via OncLive.com

Happy to have participated in this trial

Happy CAR T Anniversary Emily Whitehead #OTD 2012 #immunotherapy #TCell #tcellrx Emily Whitehead Foundation emilywhiteheadfoundation.org/our-journey/

People can make fun of California all they want but we got In-N-Out

Thank you to all our speakers and participants in making Beyond Trauma Foundation hematology and breast conference in Fresno a great success. Aaron Logan, MD, PhD, MPhil Alfred Chung Vanessa Kennedy @Mohamed Bukari @ Matthew Frank@JoeToscano #UCSFFresno

👉👉As we start ASCO European Hematology Association summer meetings, here is a summary slide I made for MRD responses in firstline CLL with combination targeted Rx. Doublets vs triplets. Marrow and PB MRD at different sensitivity at about 1 yr combo Rx. caveat- cross trial comparison #CLL

Just published the results of ASC4FIRST showing superior efficacy and safety of asciminib versus standard TKIs as frontline therapy for CML. Georgia Cancer Center Andreas Hochhaus Tim Hughes International CML Foundation nejm.org/doi/full/10.10…

He’s done. #Assad fled. #Syria is free, after 54 years of brutal tyranny. Extraordinary!

Happy to share our new paper from ⁦⁦Dana-Farber⁩ on AVO for 1L CLL with high-risk genetics just published in ⁦Journal of Clinical Oncology⁩ ascopubs.org/doi/10.1200/JC…

AQUILA trial for high risk smoldering myeloma published in NEJM today. Thanos Dimopoulos Personally for me, it is a huge milestone along 25 years of work that started in 1998. #ASH24 #ASH24VR This story below may help those interested in a clinical trialist career. 1/

Wow: Tafasitamab significantly improved outcomes when combined with R-Len in patients with relapsed follicular lymphoma. A new standard of care? Excellent presentation by Dr Sehn of InMind. #ASH24 #lymsm

I'm in the New England Journal of Medicine! I discuss the cost-effectiveness of chronic myeloid #leukemia (#CML) drugs called TKIs like newly approved #asciminib This is probably the first time anyone has cited Mark Cuban Mark Cuban Mark Cuban Cost Plus Drug Company as a reference in the NEJM!

HUGE NEWS. #Trump confirms in #Saudi that he will "order" the "cessation" of sanctions on #Syria "to give them a chance at greatness." He receives a standing ovation from the entire ballroom.

Updated STARGLO Data Show Maintained OS Benefit With Glofitamab Plus Chemo in R/R DLBCL Haifaa Abdulhaq UC San Francisco UCSF Fresno #oncology #DLBCL hubs.li/Q03nZ6Tv0

I’m excited to announce that we had a successful infusion for our first CAR-T patient today ! This is the first patient to receive CAR-T in the California Central Valley. I cannot thank our amazing team enough for their hard work which made this all possible. #UCSFFresno